Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
Tóm tắt
Từ khóa
Tài liệu tham khảo
Calfee, 2008, Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals, Infect Control Hosp Epidemiol, 29, S62, 10.1086/591061
Anderson, 2008, Strategies to prevent surgical site infections in acute care hospitals, Infect Control Hosp Epidemiol, 29, S51, 10.1086/591064
Rybak, 2009, Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, Am J Health Syst Pharm, 66, 82, 10.2146/ajhp080434
Rybak, 2009, Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists, Clin Infect Dis, 49, 325, 10.1086/600877
Klevens, 2007, Invasive methicillin-resistant Staphylococcus aureus infections in the United States, JAMA, 298, 1763, 10.1001/jama.298.15.1763
Herold, 1998, Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk, JAMA, 279, 593, 10.1001/jama.279.8.593
Liu, 2008, A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005, Clin Infect Dis, 46, 1637, 10.1086/587893
D'Agata, 2009, Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals, Clin Infect Dis, 48, 274, 10.1086/595844
Purcell, 2006, Economic impact of the community-acquired methicillin-resistant Staphylococcus aureus epidemic on the Driscoll Children's Health Plan, Pediatr Infect Dis J, 25, 178, 10.1097/01.inf.0000199304.68890.60
Noskin, 2005, The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database, Arch Intern Med, 165, 1756, 10.1001/archinte.165.15.1756
Moran, 2006, Methicillin-resistant S. aureus infections among patients in the emergency department, N Engl J Med, 355, 666, 10.1056/NEJMoa055356
Lee, 2007, Incidence and clinical characteristics of methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a large urban hospital, Am J Surg, 194, 809, 10.1016/j.amjsurg.2007.08.047
Pannaraj, 2006, Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection, Clin Infect Dis, 43, 953, 10.1086/507637
Miller, 2005, Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles, N Engl J Med, 352, 1445, 10.1056/NEJMoa042683
Wright, 2008, Pediatric mediastinitis as a complication of methicillin-resistant Staphylococcus aureus retropharyngeal abscess, Arch Otolaryngol Head Neck Surg, 134, 408, 10.1001/archotol.134.4.408
Gonzalez, 2006, Venous thrombosis associated with staphylococcal osteomyelitis in children, Pediatrics, 117, 1673, 10.1542/peds.2005-2009
Francis, 2005, Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes, Clin Infect Dis, 40, 100, 10.1086/427148
Hageman, 2006, Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season, Emerg Infect Dis, 12, 894, 10.3201/eid1206.051141
Centers for Disease Control and Prevention, 2007, Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza–Louisiana Georgia, December 2006-January 2007, MMWR Morb Mortal Wkly Rep, 56, 325
Gonzalez, 2005, Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection, Clin Infect Dis, 41, 583, 10.1086/432475
Finelli, 2008, Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection, Pediatrics, 122, 805, 10.1542/peds.2008-1336
Arnold, 2006, Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus, J Pediatr Orthop, 26, 703, 10.1097/01.bpo.0000242431.91489.b4
Crary, 2006, Venous thrombosis and thromboembolism in children with osteomyelitis, J Pediatr, 149, 537, 10.1016/j.jpeds.2006.06.067
Rutar, 2006, Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus, Ophthalmology, 113, 1455, 10.1016/j.ophtha.2006.03.031
Kravitz, 2005, Purpura fulminans due to Staphylococcus aureus, Clin Infect Dis, 40, 941, 10.1086/428573
Adem, 2005, Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children, N Engl J Med, 353, 1245, 10.1056/NEJMoa044194
Field, 1990, Institute of Medicine Committee to Advise the Public Health Service on clinical practice guidelines, clinical practice guidelines: directions for a new program, 52, 10.17226/1626
1979, Canadian Task Force on the Periodic Health Examination, Can Med Assoc J, 121, 1193
Martinez-Aguilar, 2003, Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children, Pediatr Infect Dis J, 22, 593, 10.1097/01.inf.0000073163.37519.ee
Frank, 2002, Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children, Pediatr Infect Dis J, 21, 530, 10.1097/00006454-200206000-00010
Marcinak, 2003, Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children, Curr Opin Infect Dis, 16, 265, 10.1097/00001432-200306000-00014
Nicholas, 1975, Concentration of clindamycin in human bone, Antimicrob Agents Chemother, 8, 220, 10.1128/AAC.8.2.220
Joiner, 1981, Antibiotic levels in infected and sterile subcutaneous abscesses in mice, J Infect Dis, 143, 487, 10.1093/infdis/143.3.487
Panzer, 1972, Clindamycin levels in various body tissues and fluids, J Clin Pharmacol New Drugs, 12, 259, 10.1002/j.1552-4604.1972.tb00052.x
Tsuji, 2007, Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents, Diagn Microbiol Infect Dis, 58, 41, 10.1016/j.diagmicrobio.2006.10.021
Hulten, 2006, Three-year surveillance of community onset health care-associated Staphylococcus aureus infections in children, Pediatr Infect Dis J, 25, 349, 10.1097/01.inf.0000207404.50143.1e
Chavez-Bueno, 2005, Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas, Antimicrob Agents Chemother, 49, 2283, 10.1128/AAC.49.6.2283-2288.2005
Lewis, 2005, Inducible clindamycin resistance in Staphylococci: should clinicians microbiologists be concerned?, Clin Infect Dis, 40, 280, 10.1086/426894
Raveh, 2006, Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea, Int J Antimicrob Agents, 28, 231, 10.1016/j.ijantimicag.2006.04.013
Steele, 2006, Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children, Clin Pediatr (Phila), 45, 245, 10.1177/000992280604500306
Nahum, 2006, Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks, Obstet Gynecol, 107, 1120, 10.1097/01.AOG.0000216197.26783.b5
Marty, 2006, Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis, J Clin Microbiol, 44, 595, 10.1128/JCM.44.2.595-597.2006
Vikram, 2005, Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin, J Clin Microbiol, 43, 5384, 10.1128/JCM.43.10.5384-5387.2005
Hayden, 2005, Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus, J Clin Microbiol, 43, 5285, 10.1128/JCM.43.10.5285-5287.2005
Boucher, 2007, Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus, Clin Infect Dis, 45, 601, 10.1086/520655
Friedman, 2006, Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus, Antimicrob Agents Chemother, 50, 2137, 10.1128/AAC.00039-06
Sakoulas, 2006, Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin, Antimicrob Agents Chemother, 50, 1581, 10.1128/AAC.50.4.1581-1585.2006
Patel, 2006, An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus, Clin Infect Dis, 42, 1652, 10.1086/504084
Fowler, 2006, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, 355, 653, 10.1056/NEJMoa053783
Arbeit, 2004, The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections, Clin Infect Dis, 38, 1673, 10.1086/420818
Miller, 2010, Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases, Clin Infect Dis, 50, e63, 10.1086/652656
Abdel-Rahman, 2008, Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections, Pediatr Infect Dis J, 27, 330, 10.1097/INF.0b013e318160edfc
Howe, 2003, Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid, Antimicrob Agents Chemother, 47, 3651, 10.1128/AAC.47.11.3651-3652.2003
Wootton, 2002, In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA), J Antimicrob Chemother, 50, 760, 10.1093/jac/dkf184
Bozdogan, 2003, Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center, J Antimicrob Chemother, 52, 864, 10.1093/jac/dkg457
Sanchez Garcia, 2010, Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit, JAMA, 303, 2260, 10.1001/jama.2010.757
Pillai, 2002, Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype, J Infect Dis, 186, 1603, 10.1086/345368
Arias, 2008, Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase, J Clin Microbiol, 46, 892, 10.1128/JCM.01886-07
Toh, 2007, Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid, Mol Microbiol, 64, 1506, 10.1111/j.1365-2958.2007.05744.x
Bressler, 2004, Peripheral neuropathy associated with prolonged use of linezolid, Lancet Infect Dis, 4, 528, 10.1016/S1473-3099(04)01109-0
Meissner, 2003, Hematologic effects of linezolid in young children, Pediatr Infect Dis J, 22, S186, 10.1097/01.inf.0000087021.20838.d9
Saiman, 2003, Safety and tolerability of linezolid in children, Pediatr Infect Dis J, 22, S193, 10.1097/01.inf.0000087022.58089.d8
Drew, 2000, Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy, J Antimicrob Chemother, 46, 775, 10.1093/jac/46.5.775
Sander, 2002, Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci, Intensive Care Med, 28, 1157, 10.1007/s00134-002-1358-7
Loeffler, 2002, Safety and efficacy of quinupristin/dalfopristin for treatment of invasive gram-positive infections in pediatric patients, Pediatr Infect Dis J, 21, 950, 10.1097/00006454-200210000-00013
Blaser, 1995, In vivo verification of in vitro model of antibiotic treatment of device-related infection, Antimicrob Agents Chemother, 39, 1134, 10.1128/AAC.39.5.1134
Widmer, 1990, Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections, J Infect Dis, 162, 96, 10.1093/infdis/162.1.96
Zimmerli, 1994, Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus, J Antimicrob Chemother, 33, 959, 10.1093/jac/33.5.959
Nau, 1992, Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges, J Antimicrob Chemother, 29, 719, 10.1093/jac/29.6.719
Euba, 2009, Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis, Antimicrob Agents Chemother, 53, 4305, 10.1128/AAC.00444-09
Zimmerli, 1998, Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group, JAMA, 279, 1537, 10.1001/jama.279.19.1537
Norden, 1986, Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy, South Med J, 79, 947, 10.1097/00007611-198608000-00008
Baddour, 2005, Infective endocarditis: diagnosis, antimicrobial therapy, management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America, Circulation, 111, e394
Ruhe, 2005, Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature, Clin Infect Dis, 40, 1429, 10.1086/429628
Tenover, 2006, Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States, J Clin Microbiol, 44, 108, 10.1128/JCM.44.1.108-118.2006
Bismuth, 1990, Gene heterogeneity for tetracycline resistance in Staphylococcus spp, Antimicrob Agents Chemother, 34, 1611, 10.1128/AAC.34.8.1611
Schwartz, 2009, Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300, Clin Infect Dis, 48, 1483, 10.1086/598510
Rodvold, 2006, Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose, J Antimicrob Chemother, 58, 1221, 10.1093/jac/dkl403
Fridkin, 2005, Methicillin-resistant Staphylococcus aureus disease in three communities, N Engl J Med, 352, 1436, 10.1056/NEJMoa043252
Naimi, 2003, Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection, JAMA, 290, 2976, 10.1001/jama.290.22.2976
Gorwitz, Strategies for clinical management of MRSA in the community: summary of an experts’ meeting covened by the Centers for Disease Control and Prevention, 2006
Cenizal, 2007, Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 51, 2628, 10.1128/AAC.00206-07
Szumowski, 2007, Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic, Antimicrob Agents Chemother, 51, 423, 10.1128/AAC.01244-06
Euba, 2009, Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis, Antimicrob Agents Chemother, 53, 2672, 10.1128/AAC.01504-08
Sanchez, 1997, Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection, Enferm Infecc Microbiol Clin, 15, 10
Stein, 1998, Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole), Antimicrob Agents Chemother, 42, 3086, 10.1128/AAC.42.12.3086
Adra, 2004, Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections, Ann Pharmacother, 38, 338, 10.1345/aph.1D156
Markowitz, 1992, Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection, Ann Intern Med, 117, 390, 10.7326/0003-4819-117-5-390
Hyun, 2009, Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections, Pediatr Infect Dis J, 28, 57, 10.1097/INF.0b013e3181826e5e
Antoniou, 2010, Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study, Arch Intern Med, 170, 1045, 10.1001/archinternmed.2010.142
Deresinski, 2007, Counterpoint: vancomycin Staphylococcus aureus–an antibiotic enters obsolescence, Clin Infect Dis, 44, 1543, 10.1086/518452
Kollef, 2007, Limitations of vancomycin in the management of resistant staphylococcal infections, Clin Infect Dis, 45, S191, 10.1086/519470
Sakoulas, 2004, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia, J Clin Microbiol, 42, 2398, 10.1128/JCM.42.6.2398-2402.2004
LaPlante, 2004, Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model, Antimicrob Agents Chemother, 48, 4665, 10.1128/AAC.48.12.4665-4672.2004
Small, 1990, Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users, Antimicrob Agents Chemother, 34, 1227, 10.1128/AAC.34.6.1227
Stryjewski, 2007, Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia, Clin Infect Dis, 44, 190, 10.1086/510386
Chang, 2003, Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study, Medicine (Baltimore), 82, 333, 10.1097/01.md.0000091184.93122.09
Kim, 2008, Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia, Antimicrob Agents Chemother, 52, 192, 10.1128/AAC.00700-07
Lodise, 2007, Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus, Antimicrob Agents Chemother, 51, 3731, 10.1128/AAC.00101-07
Graziani, 1988, Vancomycin concentrations in infected and noninfected human bone, Antimicrob Agents Chemother, 32, 1320, 10.1128/AAC.32.9.1320
Lamer, 1993, Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients, Antimicrob Agents Chemother, 37, 281, 10.1128/AAC.37.2.281
Cooper, 1986, Pharmacokinetics of vancomycin. Vancomycin: a comprehensive review of 30 years clinical experience, 23
Albanese, 2000, Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit, Antimicrob Agents Chemother, 44, 1356, 10.1128/AAC.44.5.1356-1358.2000
Pallin, 2008, Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus, Ann Emerg Med, 51, 291, 10.1016/j.annemergmed.2007.12.004
Edelsberg, 2009, Trends in US hospital admissions for skin and soft tissue infections, Emerg Infect Dis, 15, 1516, 10.3201/eid1509.081228
Fitch, 2007, Videos in clinical medicine. Abscess incision and drainage, N Engl J Med, 357, e20, 10.1056/NEJMvcm071319
Stevens, 2005, Practice guidelines for the diagnosis and management of skin and soft-tissue infections, Clin Infect Dis, 41, 1373, 10.1086/497143
Lee, 2004, Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus, Pediatr Infect Dis J, 23, 123, 10.1097/01.inf.0000109288.06912.21
Young, 2004, An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients, Arch Surg, 139, 947, 10.1001/archsurg.139.9.947
Rajendran, 2007, Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection, Antimicrob Agents Chemother, 51, 4044, 10.1128/AAC.00377-07
Schmitz, 2010, Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection, Ann Emerg Med, 56, 283, 10.1016/j.annemergmed.2010.03.002
Duong, 2010, Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient, Ann Emerg Med, 55, 401, 10.1016/j.annemergmed.2009.03.014
Ruhe, 2007, Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome, Clin Infect Dis, 44, 777, 10.1086/511872
Deleo, 2010, Community-associated meticillin-resistant Staphylococcus aureus, Lancet, 375, 1557, 10.1016/S0140-6736(09)61999-1
Ruhe, 2007, Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 51, 3298, 10.1128/AAC.00262-07
Purcell, 2005, Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital, Arch Pediatr Adolesc Med, 159, 980, 10.1001/archpedi.159.10.980
Moellering, 2003, Linezolid: the first oxazolidinone antimicrobial, Ann Intern Med, 138, 135, 10.7326/0003-4819-138-2-200301210-00015
Perlroth, 2008, Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature, Arch Intern Med, 168, 805, 10.1001/archinte.168.8.805
d'Oliveira, 2003, Antimicrobial susceptibility and survey of macrolide resistance mechanisms among Streptococcus pyogenes isolated in Rio de Janeiro, Brazil, Microb Drug Resist, 9, 87, 10.1089/107662903764736382
Libertin, 1983, Effects of trimethoprim-sulfamethoxazole and incubation atmosphere on isolation of group A streptococci, J Clin Microbiol, 18, 680, 10.1128/JCM.18.3.680-682.1983
Trickett, 1973, Clinical experience: respiratory tract. Trimethoprim-sulfamethoxazole versus penicillin G in the treatment of group A beta-hemolytic streptococcal pharyngitis tonsillitis, J Infect Dis, 128, 693, 10.1093/infdis/128.Supplement_3.S693
Han, 2007, High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center, J Clin Microbiol, 45, 1350, 10.1128/JCM.02274-06
Kaplan, 2005, Three-year surveillance of community-acquired Staphylococcus aureus infections in children, Clin Infect Dis, 40, 1785, 10.1086/430312
Tayal, 2006, The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department, Acad Emerg Med, 13, 384, 10.1197/j.aem.2005.11.074
Squire, 2005, ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections, Acad Emerg Med, 12, 601, 10.1197/j.aem.2005.01.016
Epperly, 1986, The value of needle aspiration in the management of cellulitis, J Fam Pract, 23, 337
Fleisher, 1980, Cellulitis: a prospective study, Ann Emerg Med, 9, 246, 10.1016/S0196-0644(80)80380-5
Fleisher, 1980, Cellulitis: bacterial etiology, clinical features, and laboratory findings, J Pediatr, 97, 591, 10.1016/S0022-3476(80)80014-X
Lee, 1985, Fine-needle aspiration biopsy in diagnosis of soft tissue infections, J Clin Microbiol, 22, 80, 10.1128/JCM.22.1.80-83.1985
Newell, 1988, Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults, J Clin Microbiol, 26, 401, 10.1128/JCM.26.3.401-404.1988
Elliott, 2009, Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus, Pediatrics, 123, e959, 10.1542/peds.2008-2428
Jeng, 2010, The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation, Medicine (Baltimore), 89, 217, 10.1097/MD.0b013e3181e8d635
Weigelt, 2005, Linezolid versus vancomycin in treatment of complicated skin soft tissue infections, Antimicrob Agents Chemother, 49, 2260, 10.1128/AAC.49.6.2260-2266.2005
Ellis-Grosse, 2005, The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam, Clin Infect Dis, 41, S341, 10.1086/431675
Stryjewski, 2008, Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms, Clin Infect Dis, 46, 1683, 10.1086/587896
Yogev, 2003, Linezolid for the treatment of complicated skin and skin structure infections in children, Pediatr Infect Dis J, 22, S172, 10.1097/01.inf.0000088671.35064.7c
Hepburn, 2004, Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis, Arch Intern Med, 164, 1669, 10.1001/archinte.164.15.1669
Miller, 2008, Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection, Clin Infect Dis, 46, 752, 10.1086/526773
Centers for Disease Control Prevention, Environmental cleaning & disinfecting for MRSA: what's the difference between cleaners, sanitizers, and disinfectants? 2010
Robicsek, 2009, Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk, Infect Control Hosp Epidemiol, 30, 623, 10.1086/597550
Laupland, 2003, Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review, Clin Infect Dis, 37, 933, 10.1086/377735
van Rijen, 2008, Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers, Cochrane Database Syst Rev, 4
Wertheim, 2004, Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study, Ann Intern Med, 140, 419, 10.7326/0003-4819-140-6-200403160-00007
Harbarth, 1999, Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 43, 1412, 10.1128/AAC.43.6.1412
Bode, 2010, Preventing surgical-site infections in nasal carriers of Staphylococcus aureus, N Engl J Med, 362, 9, 10.1056/NEJMoa0808939
Raz, 1996, A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection, Arch Intern Med, 156, 1109, 10.1001/archinte.1996.00040041109010
Ellis, 2007, Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial, Antimicrob Agents Chemother, 51, 3591, 10.1128/AAC.01086-06
Diep, 2008, Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men, Ann Intern Med, 148, 249, 10.7326/0003-4819-148-4-200802190-00204
Yang, 2010, Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections, Clin Microbiol Infect, 16, 425, 10.1111/j.1469-0691.2009.02836.x
Kazakova, 2005, A clone of methicillin-resistant Staphylococcus aureus among professional football players, N Engl J Med, 352, 468, 10.1056/NEJMoa042859
Nguyen, 2005, Recurring methicillin-resistant Staphylococcus aureus infections in a football team, Emerg Infect Dis, 11, 526, 10.3201/eid1104.041094
Romano, 2006, Outbreak of community-acquired methicillin-resistant Staphylococcus aureus skin infections among a collegiate football team, J Athl Train, 41, 141
Wiese-Posselt, 2007, Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005, Clin Infect Dis, 44, e88, 10.1086/517503
Boubaker, 2004, Panton-valentine leukocidin and staphyloccoccal skin infections in schoolchildren, Emerg Infect Dis, 10, 121, 10.3201/eid1001.030144
Whitman, 2010, Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial, Infect Control Hosp Epidemiol, 12, 1207, 10.1086/657136
American Academy of Pediatrics, Antibacterial Drugs for Newborn Infantsl, Red Book:
Wendt, 2007, Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial, Infect Control Hosp Epidemiol, 28, 1036, 10.1086/519929
Hurwitz, 1993, Atopic dermatitis, Clinical pediatric dermatology, 2nd ed, 55
Fisher, 2008, Hypochlorite killing of community-associated methicillin-resistant Staphylococcus aureus, Pediatr Infect Dis J, 27, 934, 10.1097/INF.0b013e318175d871
Loeb, 2003, Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization, Cochrane Database Syst Rev, 4
Falagas, 2007, Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials, Am J Infect Control, 35, 106, 10.1016/j.ajic.2006.09.005
Washington University School of Medicine, Staphylococcus aureus decolonization study (SuDS) (NCT00731783)
Natividad Medical Center, A prospective trial of nasal mupirocin, hexachlorophene body Wash, systemic antibiotics for prevention of recurrent methicillin resistant staphylococcus aureus infections (NCT01049438)
Los Angeles Biomedical Research Institute, A randomized clinical trial to prevent recurrent CA-MRSA infection (PRIMO) (NCT00560599)
Simor, 2007, Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization, Clin Infect Dis, 44, 178, 10.1086/510392
Miro, 2005, Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database, Clin Infect Dis, 41, 507, 10.1086/431979
Fowler, 2005, Staphylococcus aureus endocarditis: a consequence of medical progress, JAMA, 293, 3012, 10.1001/jama.293.24.3012
Levine, 1991, Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis, Ann Intern Med, 115, 674, 10.7326/0003-4819-115-9-674
Riedel, 2008, Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus, Antimicrob Agents Chemother, 52, 2463, 10.1128/AAC.00300-08
Cosgrove, 2009, Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic, Clin Infect Dis, 48, 713, 10.1086/597031
Karchmer, 1983, Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis, Rev Infect Dis, 5, S543, 10.1093/clinids/5.Supplement_3.S543
Karchmer, 1983, Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy, Ann Intern Med, 98, 447, 10.7326/0003-4819-98-4-447
Figueroa, 2009, Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program, Clin Infect Dis, 49, 177, 10.1086/600039
Benvenuto, 2006, Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers, Antimicrob Agents Chemother, 50, 3245, 10.1128/AAC.00247-06
Rose, 2008, Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations, Antimicrob Agents Chemother, 52, 831, 10.1128/AAC.00869-07
Rose, 2007, Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies, J Antimicrob Chemother, 60, 334, 10.1093/jac/dkm170
Rose, 2008, Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations, Antimicrob Agents Chemother, 52, 3061, 10.1128/AAC.00102-08
Silverman, 2005, Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact, J Infect Dis, 191, 2149, 10.1086/430352
Rehm, 2008, Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates, J Antimicrob Chemother, 62, 1413, 10.1093/jac/dkn372
Ardura, 2007, Daptomycin therapy for invasive gram-positive bacterial infections in children, Pediatr Infect Dis J, 26, 1128, 10.1097/INF.0b013e31814523f8
Chandorkar, 2009, Pharmacokinetics (PK) and safety of 8 and 10 mg/kg of daptomycin in pediatric patients aged 2 to 6 years. [abstract number 1243], Program and abstracts of the 47th annual meeting of the Infectious Diseases Society of America
Boucher, 2006, Appropriateness of two-week therapy for catheter-related S. aureus bacteremia [abstract number L-1204], Program and abstracts of the 46th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Jernigan, 1993, Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis, Ann Intern Med, 119, 304, 10.7326/0003-4819-119-4-199308150-00010
Cosgrove, 2008, Management of methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis, 46, S386, 10.1086/533595
Dworkin, 1989, Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin, Lancet, 2, 1071, 10.1016/S0140-6736(89)91083-0
Heldman, 1996, Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy, Am J Med, 101, 68, 10.1016/S0002-9343(96)00070-8
Fowler, 1997, Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients, J Am Coll Cardiol, 30, 1072, 10.1016/S0735-1097(97)00250-7
Sullenberger, 2005, Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia, J Heart Valve Dis, 14, 23
Abraham, 2004, Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S. aureus and methicillin-resistant S. aureus bacteremia, Am Heart J, 147, 536, 10.1016/j.ahj.2003.09.018
Reynolds, 2003, Sensitivity of transthoracic versus transesophageal echocardiography for the detection of native valve vegetations in the modern era, J Am Soc Echocardiogr, 16, 67, 10.1067/mje.2003.43
Valente, 2005, Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia, Pediatrics, 115, e15, 10.1542/peds.2004-1152
Fowler, 1998, Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients, Clin Infect Dis, 27, 478, 10.1086/514686
Chamis, 2001, Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators, Circulation, 104, 1029, 10.1161/hc3401.095097
Baddour, 2010, Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association, Circulation, 121, 458, 10.1161/CIRCULATIONAHA.109.192665
Vikram, 2003, Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis, JAMA, 290, 3207, 10.1001/jama.290.24.3207
D'Agostino, 1985, Valve replacement in patients with native valve endocarditis: what really determines operative outcome?, Ann Thorac Surg, 40, 429, 10.1016/S0003-4975(10)60097-5
Mullany, 1989, The surgical treatment of infective endocarditis, World J Surg, 13, 132, 10.1007/BF01671175
John, 1998, Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death, Clin Infect Dis, 26, 1302, 10.1086/516378
Bishara, 2001, Long-term outcome of infective endocarditis: the impact of early surgical intervention, Clin Infect Dis, 33, 1636, 10.1086/323785
Remadi, 2007, Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis, Ann Thorac Surg, 83, 1295, 10.1016/j.athoracsur.2006.09.093
Lobo, 2010, Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia, Chest, 138, 130, 10.1378/chest.09-1562
Combes, 2004, Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia, Am J Respir Crit Care Med, 170, 786, 10.1164/rccm.200403-346OC
Shorr, 2006, Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy, Crit Care Med, 34, 700, 10.1097/01.CCM.0000201885.57697.21
Zahar, 2005, Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?, Clin Infect Dis, 41, 1224, 10.1086/496923
Cruciani, 1996, Penetration of vancomycin into human lung tissue, J Antimicrob Chemother, 38, 865, 10.1093/jac/38.5.865
Jung, 2010, Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia, Crit Care Med, 38, 175, 10.1097/CCM.0b013e3181b9ecea
Conte, 2002, Intrapulmonary pharmacokinetics of linezolid, Antimicrob Agents Chemother, 46, 1475, 10.1128/AAC.46.5.1475-1480.2002
Rubinstein, 2001, Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study, Clin Infect Dis, 32, 402, 10.1086/318486
Wunderink, 2003, Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia, Clin Ther, 25, 980, 10.1016/S0149-2918(03)80118-2
Wunderink, 2003, Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia, Chest, 124, 1789, 10.1016/S0012-3692(15)33412-7
Wunderink, 2008, Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus, Chest, 134, 1200, 10.1378/chest.08-0011
Kimura, 1998, Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients, J Trauma, 45, 383, 10.1097/00005373-199808000-00032
Mathews, 2008, Septic arthritis: current diagnostic and therapeutic algorithm, Curr Opin Rheumatol, 20, 457, 10.1097/BOR.0b013e3283036975
Sia, 2006, Infection and musculoskeletal conditions: osteomyelitis, Best Pract Res Clin Rheumatol, 20, 1065, 10.1016/j.berh.2006.08.014
Darley, 2004, Antibiotic treatment of gram-positive bone and joint infections, J Antimicrob Chemother, 53, 928, 10.1093/jac/dkh191
Stengel, 2001, Systematic review and meta-analysis of antibiotic therapy for bone and joint infections, Lancet Infect Dis, 1, 175, 10.1016/S1473-3099(01)00094-9
Daver, 2007, Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis, J Infect, 54, 539, 10.1016/j.jinf.2006.11.011
Dombrowski, 2008, Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections, J Infect, 57, 110, 10.1016/j.jinf.2008.04.003
Al-Nammari, 2007, Hematogenous methicillin-resistant Staphylococcus aureus spondylodiscitis, Spine (Phila Pa 1976), 32, 2480, 10.1097/BRS.0b013e318157393e
Tice, 2003, Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy, Am J Med, 114, 723, 10.1016/S0002-9343(03)00231-6
Van der Auwera, 1985, Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections, Antimicrob Agents Chemother, 28, 467, 10.1128/AAC.28.4.467
Priest, 2005, Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes, South Med J, 98, 854, 10.1097/01.smj.0000168666.98129.33
Livorsi, 2008, Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA, J Infect, 57, 128, 10.1016/j.jinf.2008.04.012
Crompton, 2009, Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry, J Chemother, 21, 414, 10.1179/joc.2009.21.4.414
Lamp, 2007, Clinical experience with daptomycin for the treatment of patients with osteomyelitis, Am J Med, 120, S13, 10.1016/j.amjmed.2007.07.010
Shipton, 2007, Experience with daptomycin in Staphylococcus bone and joint infections: case series and emergence of nonsusceptibility, Infect Dis Clin Pract, 15, 324, 10.1097/IPC.0b013e318142cbbf
Skiest, 2006, Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin, J Clin Microbiol, 44, 655, 10.1128/JCM.44.2.655-656.2006
Martinez-Aguilar, 2004, Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children, Pediatr Infect Dis J, 23, 701, 10.1097/01.inf.0000133044.79130.2a
Broder, 2004, Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis, Ann Plast Surg, 52, 385, 10.1097/01.sap.0000106888.60963.18
Chen, 2007, Experience with linezolid therapy in children with osteoarticular infections, Pediatr Infect Dis J, 26, 985, 10.1097/INF.0b013e31812e62dc
Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin Infect Dis, 38, 521, 10.1086/381202
Rao, 2007, Efficacy and safety of linezolid for gram-positive orthopedic infections: a prospective case series, Diagn Microbiol Infect Dis, 59, 173, 10.1016/j.diagmicrobio.2007.04.006
Rayner, 2004, Linezolid in the treatment of osteomyelitis: results of compassionate use experience, Infection, 32, 8, 10.1007/s15010-004-3029-9
Jensen, 1998, Bacteremic Staphylococcus aureus spondylitis, Arch Intern Med, 158, 509, 10.1001/archinte.158.5.509
Simpson, 2001, Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival, J Bone Joint Surg Br, 83, 403, 10.1302/0301-620X.83B3.0830403
Barberan, 2006, Conservative treatment of staphylococcal prosthetic joint infections in elderly patients, Am J Med, 119, e7, 10.1016/j.amjmed.2006.03.036
Aboltins, 2007, Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid, Clin Microbiol Infect, 13, 586, 10.1111/j.1469-0691.2007.01691.x
Kowalski, 2007, The management and outcome of spinal implant infections: contemporary retrospective cohort study, Clin Infect Dis, 44, 913, 10.1086/512194
Zalavras, 2009, Infection following operative treatment of ankle fractures, Clin Orthop Relat Res, 467, 1715, 10.1007/s11999-009-0743-8
Carrillo-Marquez, 2009, USA-300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children, Pediatr Infect Dis J, 28, 1076, 10.1097/INF.0b013e3181adbcfe
Peltola, 2009, Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis, Clin Infect Dis, 48, 1201, 10.1086/597582
Ballock, 2009, A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis, J Pediatr Orthop, 29, 636, 10.1097/BPO.0b013e3181b2b860
Pfausler, 2003, Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy, J Neurosurg, 98, 1040, 10.3171/jns.2003.98.5.1040
Jorgenson, 2007, Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices, Pediatr Neurosurg, 43, 449, 10.1159/000108786
Wang, 2008, Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients, Surg Neurol, 69, 126, 10.1016/j.surneu.2007.01.073
Myrianthefs, 2006, Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients, Antimicrob Agents Chemother, 50, 3971, 10.1128/AAC.00051-06
Beer, 2007, Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains, Antimicrob Agents Chemother, 51, 379, 10.1128/AAC.00515-06
Nagashima, 2008, Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report, J Infect Chemother, 14, 147, 10.1007/s10156-007-0582-Z
Dudley, 1984, Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges, Antimicrob Agents Chemother, 26, 811, 10.1128/AAC.26.6.811
Levitz, 1984, Trimethoprim-sulfamethoxazole for bacterial meningitis, Ann Intern Med, 100, 881, 10.7326/0003-4819-100-6-881
Gerber, 2006, Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis, J Antimicrob Chemother, 57, 720, 10.1093/jac/dkl007
Cottagnoud, 2004, Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis, Antimicrob Agents Chemother, 48, 3928, 10.1128/AAC.48.10.3928-3933.2004
Lu, 2000, Adults with meningitis caused by oxacillin-resistant Staphylococcus aureus, Clin Infect Dis, 31, 723, 10.1086/314034
Chang, 2001, Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains, Infection, 29, 245, 10.1007/s15010-001-1092-z
von Specht, 2006, Methicillin-resistant Staphylococcus aureus in community-acquired meningitis, Eur J Clin Microbiol Infect Dis, 25, 267, 10.1007/s10096-006-0124-0
Dylewski, 2004, A case of spontaneous methicillin-resistant Staphylococcus aureus meningitis in a health care worker, Can J Infect Dis Med Microbiol, 15, 336, 10.1155/2004/125983
Pintado, 2002, Clinical study of 44 cases of Staphylococcus aureus meningitis, Eur J Clin Microbiol Infect Dis, 21, 864, 10.1007/s10096-002-0814-1
Lodise, 2008, Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity, Antimicrob Agents Chemother, 52, 1330, 10.1128/AAC.01602-07
Gallagher, 2008, Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin, J Infect, 57, 410, 10.1016/j.jinf.2008.06.023
Kessler, 2007, Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid, Infection, 35, 271, 10.1007/s15010-007-6211-z
Naesens, 2009, Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus, J Med Microbiol, 58, 1247, 10.1099/jmm.0.011130-0
Ntziora, 2007, Linezolid for the treatment of patients with central nervous system infection, Ann Pharmacother, 41, 296, 10.1345/aph.1H307
Vartzelis, 2005, Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant, Infection, 33, 36, 10.1007/s15010-005-4062-z
Lee, 2008, Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin, Clin Infect Dis, 47, 588, 10.1086/590257
Schreffler, 2002, Treatment of cerebrospinal fluid shunt infections: a decision analysis, Pediatr Infect Dis J, 21, 632, 10.1097/00006454-200207000-00006
Whitehead, 2001, The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons, Pediatr Neurosurg, 35, 205, 10.1159/000050422
Sacar, 2006, A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period, BMC Infect Dis, 6, 43, 10.1186/1471-2334-6-43
Brown, 2006, Conservative management of patients with cerebrospinal fluid shunt infections, Neurosurgery, 58, 657, 10.1227/01.NEU.0000204126.54417.46
Amod, 2005, Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin, J Infect, 50, 252, 10.1016/j.jinf.2004.04.002
Elvy, 2008, Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin, J Antimicrob Chemother, 61, 461, 10.1093/jac/dkm501
Southwick, 1986, Septic thrombosis of the dural venous sinuses, Medicine (Baltimore), 65, 82, 10.1097/00005792-198603000-00002
Bhatia, 2002, Septic cavernous sinus thrombosis secondary to sinusitis: are anticoagulants indicated? A review of the literature, J Laryngol Otol, 116, 667, 10.1258/002221502760237920
Stevens, 2007, Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus, J Infect Dis, 195, 202, 10.1086/510396
Schlievert, 1984, Clindamycin-induced suppression of toxic-shock syndrome–associated exotoxin production, J Infect Dis, 149, 471, 10.1093/infdis/149.3.471
Stevens, 2006, Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics, Clin Infect Dis, 42, 729, 10.1086/500265
Bernardo, 2004, Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression, Antimicrob Agents Chemother, 48, 546, 10.1128/AAC.48.2.546-555.2004
Ho, 1986, In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus, Diagn Microbiol Infect Dis, 4, 133, 10.1016/0732-8893(86)90147-1
Jacqueline, 2003, In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods, J Antimicrob Chemother, 51, 857, 10.1093/jac/dkg160
Grohs, 2003, In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus, Antimicrob Agents Chemother, 47, 418, 10.1128/AAC.47.1.418-420.2003
Booker, 2004, In vitro antagonism with the combination of vancomycin and clindamycin against Staphylococcus aureus, J Appl Res, 4, 385
Chiang, 2003, Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 47, 3002, 10.1128/AAC.47.9.3002-3004.2003
Micek, 2005, Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production, Chest, 128, 2732, 10.1378/chest.128.4.2732
Yanagisawa, 2007, Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin, J Infect Chemother, 13, 368, 10.1007/s10156-007-0551-6
Darenberg, 2004, Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome, Clin Infect Dis, 38, 836, 10.1086/381979
Brown, 2009, Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton-Valentine leukocidin, Clin Vaccine Immunol, 16, 139, 10.1128/CVI.00360-08
Yoong, 2010, Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection, Proc Natl Acad Sci U S A, 107, 2241, 10.1073/pnas.0910344107
Pildal, 2004, Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review, Clin Infect Dis, 39, 38, 10.1086/421089
Kreymann, 2007, Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock, Crit Care Med, 35, 2677
Laupland, 2007, Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis, Crit Care Med, 35, 2686
Turgeon, 2007, Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis, Ann Intern Med, 146, 193, 10.7326/0003-4819-146-3-200702060-00009
Dellinger, 2008, Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008, Crit Care Med, 36, 296, 10.1097/01.CCM.0000298158.12101.41
Mohr, 2007, Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus, Clin Infect Dis, 44, 1536, 10.1086/518451
Mohammedi, 2006, Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg, Int J Antimicrob Agents, 27, 259, 10.1016/j.ijantimicag.2005.11.009
Wang, 2001, Necessity of a loading dose when using vancomycin in critically ill patients, J Antimicrob Chemother, 47, 246, 10.1093/jac/47.2.246
James, 1996, Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections, Antimicrob Agents Chemother, 40, 696, 10.1128/AAC.40.3.696
Lacy, 2000, Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci, Int J Antimicrob Agents, 15, 25, 10.1016/S0924-8579(00)00121-7
Wysocki, 1995, Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections, J Antimicrob Chemother, 35, 352, 10.1093/jac/35.2.352
Ebert, 1987, In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and resistant S. aureus [abstract 439], Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemother
Dudley, 1999, Pharmacokinetic-pharmacodynamic indices for vancomycin treatment of susceptible intermediate S. aureus in the neutropenic murine thigh model [abstract 2031], Program and Abstracts of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy
Moise, 2000, Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus, Am J Health Syst Pharm, 57, S4, 10.1093/ajhp/57.suppl_2.S4
Moise-Broder, 2004, Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections, Clin Pharmacokinet, 43, 925, 10.2165/00003088-200443130-00005
Jeffres, 2006, Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices, Chest, 130, 947, 10.1378/chest.130.4.947
Charles, 2004, Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus, Clin Infect Dis, 38, 448, 10.1086/381093
Lodise, 2008, Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin, Antimicrob Agents Chemother, 52, 3315, 10.1128/AAC.00113-08
Hidayat, 2006, High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity, Arch Intern Med, 166, 2138, 10.1001/archinte.166.19.2138
Maor, 2009, Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia, J Infect Dis, 199, 619, 10.1086/596629
Lipsky, 2005, Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections, J Antimicrob Chemother, 55, 240, 10.1093/jac/dkh531
Breedt, 2005, Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam, Antimicrob Agents Chemother, 49, 4658, 10.1128/AAC.49.11.4658-4666.2005
Lee-Such, 2006, Nephrotoxicity associated with aggressive vancomycin therapy [abstract #1298], Program and abstracts of the 46th annual meeting of the Interscience Conference on antimicrobial agents Chemotherapy
Jeffres, 2007, A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia, Clin Ther, 29, 1107, 10.1016/j.clinthera.2007.06.014
Forouzesh, 2009, Vancomycin ototoxicity: a reevaluation in an era of increasing doses, Antimicrob Agents Chemother, 53, 483, 10.1128/AAC.01088-08
Frymoyer, 2009, Current recommended dosing of vancomycin for children with invasive methicillin-resistant staphylococcus aureus infections is inadequate, Pediatr Infect Dis J, 28, 398, 10.1097/INF.0b013e3181906e40
Odio, 1984, Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children, J Pediatr, 105, 491, 10.1016/S0022-3476(84)80036-0
Fridkin, 2003, Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001, Clin Infect Dis, 36, 429, 10.1086/346207
Moore, 2003, Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis, Antimicrob Agents Chemother, 47, 1262, 10.1128/AAC.47.4.1262-1266.2003
Walsh, 2001, Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides, J Clin Microbiol, 39, 2439, 10.1128/JCM.39.7.2439-2444.2001
Liu, 2003, Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods, Antimicrob Agents Chemother, 47, 3040, 10.1128/AAC.47.10.3040-3045.2003
Tenover, 2009, Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy, Int J Antimicrob Agents, 33, 564, 10.1016/j.ijantimicag.2008.12.010
Wootton, 2001, A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital, J Antimicrob Chemother, 47, 399, 10.1093/jac/47.4.399
Tenover, 2007, The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus, Clin Infect Dis, 44, 1208, 10.1086/513203
Wootton, 2007, A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides, J Clin Microbiol, 45, 329, 10.1128/JCM.01508-06
Yusof, 2008, Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA, J Clin Microbiol, 46, 3042, 10.1128/JCM.00265-08
Leonard, 2009, Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides, J Antimicrob Chemother, 63, 489, 10.1093/jac/dkn520
Swenson, 2009, Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus, J Clin Microbiol, 47, 2013, 10.1128/JCM.00221-09
Wang, 2006, Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period, J Clin Microbiol, 44, 3883, 10.1128/JCM.01388-06
Steinkraus, 2007, Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05, J Antimicrob Chemother, 60, 788, 10.1093/jac/dkm258
Moise-Broder, 2004, Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy, Clin Infect Dis, 38, 1700, 10.1086/421092
Soriano, 2008, Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis, 46, 193, 10.1086/524667
Alos, 2008, Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage, J Antimicrob Chemother, 62, 773, 10.1093/jac/dkn246
Holmes, 2008, Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006, Antimicrob Agents Chemother, 52, 757, 10.1128/AAC.00945-07
Jones, 2006, Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains, Clin Infect Dis, 42, S13, 10.1086/491710
Sader, 2009, Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006, Antimicrob Agents Chemother, 53, 4127, 10.1128/AAC.00616-09
Wikler, 2006, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-seventh edition, M7
Prakash, 2008, Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used, Antimicrob Agents Chemother, 52, 4528, 10.1128/AAC.00904-08
Mason, 2009, Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005, Journal of Clinical Microbiology, 47, 1682, 10.1128/JCM.00407-09
Hawkins, 2007, Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes, Arch Intern Med, 167, 1861, 10.1001/archinte.167.17.1861
Smith, 2005, Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against gram-positive bacterial isolates from a large cancer center, Diagn Microbiol Infect Dis, 52, 255, 10.1016/j.diagmicrobio.2005.02.015
Cha, 2003, Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations, Antimicrob Agents Chemother, 47, 3960, 10.1128/AAC.47.12.3960-3963.2003
Moise, 2008, Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia, J Antimicrob Chemother, 61, 85, 10.1093/jac/dkm445
Pillai, 2007, Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF, Antimicrob Agents Chemother, 51, 2223, 10.1128/AAC.00202-07
Cui, 2006, Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate staphylococcus aureus, Antimicrob Agents Chemother, 50, 1079, 10.1128/AAC.50.3.1079-1082.2006
Hirschwerk, 2006, Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia, Infect Control Hosp Epidemiol, 27, 315, 10.1086/502688
Kullar, 2009, High-dose daptomycin for complicated gram-positive infections [poster # 1984]
Credito, 2007, Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology, Antimicrob Agents Chemother, 51, 1504, 10.1128/AAC.01455-06
Baltch, 2008, Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth, Antimicrob Agents Chemother, 52, 1829, 10.1128/AAC.01480-07
Tsuji, 2005, Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations, Antimicrob Agents Chemother, 49, 2735, 10.1128/AAC.49.7.2735-2745.2005
Sakoulas, 2003, Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 47, 1714, 10.1128/AAC.47.5.1714-1718.2003
Miro, 2009, Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 53, 4172, 10.1128/AAC.00051-09
Rybak, 1999, Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity, Antimicrob Agents Chemother, 43, 1549, 10.1128/AAC.43.7.1549
Proctor, 2008, Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection, Clin Infect Dis, 46, 584, 10.1086/525536
Schwalm, 2004, Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment, Can J Infect Dis, 15, 97
Munoz, 2007, Linezolid therapy for infective endocarditis, Clin Microbiol Infect, 13, 211, 10.1111/j.1469-0691.2006.01585.x
Falagas, 2006, Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence, J Antimicrob Chemother, 58, 273, 10.1093/jac/dkl219
Jang, 2009, Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem, Clin Infect Dis, 49, 395, 10.1086/600295
Gebhart, 2007, Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid rifampin, Pharmacotherapy, 27, 476, 10.1592/phco.27.3.476
Egle, 2005, Linezolid and rifampin: drug interaction contrary to expectations?, Clin Pharmacol Ther, 77, 451, 10.1016/j.clpt.2005.01.020
Gandelman, 2010, Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism, J Clin Pharmacol
Nace, 2010, Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin, J Antimicrob Chemother, 65, 1315, 10.1093/jac/dkq113
Climo, 1999, Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin, Antimicrob Agents Chemother, 43, 1747, 10.1128/AAC.43.7.1747
Fox, 2006, Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics, Antimicrob Agents Chemother, 50, 2951, 10.1128/AAC.00232-06
Yang, 2010, Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the “seesaw effect”), Antimicrob Agents Chemother, 54, 3161, 10.1128/AAC.00487-10
Fortunov, 2007, Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates, Pediatrics, 120, 937, 10.1542/peds.2007-0956
Tan, 1993, Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia, Antimicrob Agents Chemother, 37, 2401, 10.1128/AAC.37.11.2401
Deville, 2003, Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates, Pediatr Infect Dis J, 22, S158, 10.1097/01.inf.0000086955.93702.c7